Li Yan, Liang Mingqiang, Lin Yuxiang, Lv Jinxing, Chen Minyan, Zhou Peng, Fu Fangmeng, Wang Chuan
Breast Surgery Ward, Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province 350001, China.
Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province 350001, China.
J Oncol. 2020 Sep 9;2020:4270957. doi: 10.1155/2020/4270957. eCollection 2020.
CXCLs play critical roles in antitumor immunity by activating tumor-specific immune responses and stimulating tumor proliferation, thus affecting patient outcomes. However, the expression and prognostic values of CXCLs in breast cancer have not been well clarified. The aim of this study was to investigate the impact of CXCLs transcriptional expression on breast cancer patients. Oncomine database, GEPIA (Gene Expression Profiling Interactive Analysis), UALCAN, Kaplan-Meier Plotter, TIMER (Tumor Immune Estimation Resource), and DAVID were used in our study. The transcriptional levels of CXCL9/10/11/13 in breast cancer tissues were significantly elevated while the transcriptional levels of CXCL1/2/3/12 were decreased based on intersections of Oncomine database and GEPIA. Among them, breast cancer patients with high transcriptional levels of CXCL2/9/10/12/13 and low transcriptional level of CXCL3 were associated with a better prognosis. We also found that most of CXCLs expressions are significantly correlated with known prognostic factors, such as patient's age, major subclasses, individual cancer stages, and nodal metastasis status. In addition, the expression of CXCL9/10/12/13 was also indicated to be correlated with the infiltration of six types of immune cells (B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells). The functions of differentially expressed CXCLs are primarily related to the immune response and cytokine-cytokine receptor interactions. Our results may provide novel evidence of new prognostic or predictive biomarkers for breast cancer patients.
趋化因子（CXCLs）通过激活肿瘤特异性免疫反应和刺激肿瘤增殖在抗肿瘤免疫中发挥关键作用，从而影响患者的预后。然而，CXCLs在乳腺癌中的表达及预后价值尚未完全明确。本研究旨在探讨CXCLs转录表达对乳腺癌患者的影响。我们的研究使用了Oncomine数据库、GEPIA（基因表达谱交互式分析）、UALCAN、Kaplan-Meier Plotter、TIMER（肿瘤免疫估计资源）和DAVID。基于Oncomine数据库和GEPIA的交集分析，乳腺癌组织中CXCL9/10/11/13的转录水平显著升高，而CXCL1/2/3/12的转录水平降低。其中，CXCL2/9/10/12/13转录水平高且CXCL3转录水平低的乳腺癌患者预后较好。我们还发现，大多数CXCLs的表达与已知的预后因素显著相关，如患者年龄、主要亚类、个体癌症分期和淋巴结转移状态。此外，CXCL9/10/12/13的表达还与六种免疫细胞（B细胞、CD8 + T细胞、CD4 + T细胞、巨噬细胞、中性粒细胞和树突状细胞）的浸润相关。差异表达的CXCLs的功能主要与免疫反应和细胞因子-细胞因子受体相互作用有关。我们的结果可能为乳腺癌患者提供新的预后或预测生物标志物的新证据。
